|
Workshop
[In-Person] Preclinical Development and IND Filing for Antibody-Based Therapeutics: Nuts, Bolts and Best Practices
Speakers:
Laurence Fayadat-Dilman (Merck and Co), Keegan Cooke (Amgen), Jay Tibbitts (Surrozen), Robert Caldwell (AbbVie), Lilia Koriazova (Erasca), Sara Glickstein Bar-Zeev (Genentech); Key Kang (Genentech), Arianne L. Motter (FDA)
Organizers:
Ayse Meric Ovacik (Genentech); Smita Salian-Mehta (Gilead); Isabel Figueroa Amenabar (Amgen); Laurence Fayadat-Dilman (Merck and Co); Minli Xie (Erasca); Snow Ge (Biobridge Pharma); Shichang Miao (Amgen)
Date:
2023-05-24
Time:
8:45-17:25 Pacific Time
Registration fee:
Regular attendees: $295; Academic/Students/Postdocs: $125; Major Sponsorship: $3000; Vendor Show: $695; On-site Registration:$500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(23)Abzena; Alturas Analytics; Biointron; BioTether Sciences; Charles River Labs; CHIRON Recombinant Proteins; Correlia Biosystems Inc; CP Lab Safety; Ellegaard BioResearch; Emery Pharma; Frontage Laboratories; Gator Bio; GBI Bio; Inotiv; IRBM; KCAS Bio; Meadowhawk Biolabs; Medicilon; MilliporeSigma; Novogene Corporation Inc.; Q2Lab Solutions; QPS, LLC; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2023-05-23
(it will close sooner if the seating cap is reached)
About the Topic
Commercial clinical pipeline of mAbs has vastly increased in recent years; the mAbs based therapeutics in development has been growing at an incredible pace. The investigational new drug application (IND) application is an important step to achieve in mAb based therapeutics, and understanding the requirements for a successful IND filing is utmost important to ensure fast and efficient development. While the principles and basics are similar across different modalities for an IND filing such as safety studies, there are important aspects that need to be considered for mAb based therapeutics. In this workshop, we will cover the best practices for a successful IND package of mAbs. Our highly experienced speakers will discuss the preclinical studies for mAb based therapeutics IND packages. This workshop will be suitable for novice drug developers and small molecule drug development experts who are interested in mAb therapeutic development.
Topics to be covered:
- Overview of preclinical development and IND filing requirements for antibody-based therapeutics
- Required preclinical studies for
Safety assessment Pharmacology Pharmacokinetics CMC (Chemistry, Manufacturing, Control)
- Clinical development plans
- FDA’s perspective by an FDA reviewer
Time (PT)
|
Topic
|
Presenter
|
8:45-9:00 am
|
PBSS Welcome and Introduction
|
Snow Ge (BridgeBio Pharma)
|
9:00-9:20 am
|
1. Overview of preclinical development and IND filing requirements for antibody-based therapeutics
|
Ayse Meric Ovacik, PhD, Senior Principal Scientist, Genentech
|
9:20-9:50 am
|
2. Overview of antibody-based therapeutics: structure, generation, design, and optimization
|
Laurence Fayadat-Dilman, PhD, Executive Director, Discovery Biologics, Merck & Co, Inc.
|
9:50-10:25 am
|
3- Non-clinical pharmacology considerations for bi-specific antibodies
|
Keegan Cooke, BA, Principal Scientist
Oncology Research, Amgen
|
10:25-10:35 am
|
Major Sponsor’s Presentation
|
Mycenax Biotech Inc.
|
10:35-10:50am
|
Break Period & Vendor Show
|
-
|
10:50-11:45am
|
4- Pharmacokinetic/Pharmacodynamic and bioanalytical considerations for successful IND filings
|
Jay Tibbitts, DVM, PhD, Vice President Non-Clinical Development, Surrozen
|
11:45-12:35pm
|
Lunch
|
|
12:35-1:45pm
|
5- Preclinical toxicology points to consider for biotherapeutic IND submissions
|
Robert Caldwell, PhD, Senior Principal Research Scientist, Toxicology, AbbVie
|
1:45-2:45pm
|
6. IND-enabling CMC activities for therapeutic antibodies
|
Lilia Koriazova, PhD, Sr. Director, Biologics Pharmaceutical Sciences, R&D department, Erasca
|
2:45-2:55pm
|
Major Sponsor’s Presentation
|
Veloxity Labs
|
2:55-3:10pm
|
Break
|
-
|
3:10-3:45pm
|
7- Clinical Development Plan
|
Sara Glickstein Bar-Zeev, PhD, Senior Clinical Scientist, Genentech
|
3:45-4:15pm
|
8. Regulatory strategies and Interactions with FDA: Industry perspective & how to prepare for FDA meetings
|
Key Kang, MSc, Global Regulatory Leader and Group Director, Genentech Inc.
|
4:15-4:50pm
|
9- INDs for biologics: The regulatory perspective
|
Arianne Motter, PhD, DABT, Senior Toxicologist/CDER/OND/DPT-ID, U.S FDA
|
4:50-5:25pm
|
Panel Discussion
|
All Speakers
|
5:25-6:25pm
|
Happy Hour
|
Sponsor: Alturas Analytics
|
2024-08-14, [Free Online] Advances in Cancer Therapeutics (Organized by PBSS and BioScience Forum)
|
2024-08-22, [Free Online] Diabetes and Obesity Treatments: Current and Emerging Landscapes of GLP-1, GIP, and Beyond
|
2024-09-10, [In-Person] Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities
|
2024-09-20, [In-Person] Nonclinical Safety Assessments of Biologics and Other Novel Modalities for IND/NDA/BLA Filings
|
2024-09-25, [Free Online] Development of Protein Degraders: Computational Modeling, Medicinal Chemistry and Early Development
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|
2024-10-25, [Free Online Workshop] Unleashing the Power of Real-World Evidence / Data (RWE/RWD) to Facilitate Drug Discovery, Development, and Beyond
|
2024-11-01, [In-Person] Clinical Pharmacology Studies on Hepatic and Renal Impairments for NDA Filing: Strategies, Design, Conduct, Analysis and Regulatory Aspects
|
2024-11-13, [Free Online Workshop] Career Transition for Research Scientists: Business Development & BioPartnering
|
2024-11-15, [In-Person] Bioanalysis for Biologics and Cell/Gene Therapy Products: Refining Established Approaches for New Complex Therapeutics
|
2025-01-22, [In-Person] Small-Molecule Formulation for Discovery & Early Development (jointly by PBSS / AAPS-BADG / Syner-G)
|
|
Ads (in random order)
Submit a Text Ad ($250 for 2 months)
Simulations Plus
GastroPlus X: Science, models & refined algorithms—now with intuitive interface, faster processing & streamlined workflows for faster PBPK modeling.
|
Alturas Analytics, Inc.
Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
|
Submit a Text Ad
|